Publication date: Jul 02, 2024

We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, phase 2/3, open-label, clinical trial of a single dose (30 μg) of an Omicron XBB. 1.5-adapted BNT162b2 monovalent mRNA vaccine. The trial included healthy participants who had received at least three previous doses of an mRNA vaccine authorized in the United States, with the most recent authorized vaccine dose being a bivalent Omicron BA. 4/BA. 5-adapted vaccine given at least 150 days before the study vaccination. In this analysis, Omicron XBB. 1.5, BA. 2.86, and JN. 1 serum neutralizing titers were assessed at baseline and at 1 month after vaccination. Analyses were conducted in a subset of participants who were at least 18 years of age (N = 40) and who had evidence of previous SARS-CoV-2 infection. Immunogenicity was also evaluated in a group of participants who received bivalent BA. 4/BA. 5-adapted BNT162b2 in another study (ClinicalTrials. gov Identifier: NCT05472038) and who were matched demographically to the participants in the current trial. In this analysis, monovalent XBB. 1.5-adapted BNT162b2 vaccine elicited higher XBB. 1.5, BA. 2.86, and JN. 1 neutralizing titers than those elicited by bivalent BA. 4/BA. 5-adapted BNT162b2. Overall geometric mean fold rises in neutralizing titers from baseline to 1 month after vaccination were higher among participants who received XBB. 1.5-adapted BNT162b2 than those who received bivalent BA. 4/BA. 5-adapted BNT162b2 for XBB. 1.5 (7. 6 vs. 5. 6), slightly higher for JN. 1 (3. 9 vs. 3. 5), and similar for BA. 2.86 (4. 8 vs. 4. 9). ClinicalTrials. gov Identifier: NCT05997290.

Open Access PDF

Semantics

Original Article